Sustained co-delivery of gemcitabine and cis-platinum via biodegradable thermo-sensitive hydrogel for synergistic combination therapy of pancreatic cancer
- 22 Downloads
Pancreatic cancer is one of the most devastating cancers with poor prognosis and no significant change in the survival rate over the past decades. Localized targeted drug delivery through interventional endoscopic ultrasonography-guided fine-needle injection (EUS-FNI) is an attractive and minimally invasive strategy for inoperable pancreatic cancer. An injectable in-situ formed long-lasting drug delivery system is a promising alternative for the localized treatment of pancreatic cancer via EUS-FNI. Here, a biodegradable thermo-sensitive copolymer hydrogel for the co-delivery of anticancer agents gemcitabine (GEM) and cis-platinum (DDP) was developed. This hydrogel is a free flowable liquid at room temperature that changes into a semi-solid hydrogel following injection in response to the physiological temperature. Both in vitro and in vivo drug release behaviors indicate sustained drug release of this delivery system. Synergistic cellular proliferation inhibition and desirable apoptosis promotion have been found when pancreatic cancer Bxpc-3 cells were co-cultured with this GEM-DDP/hydrogel system. After a single intratumoral injection, the dual-drug loaded hydrogel formulation exhibited superior anti-tumor efficacy and minimized systemic side effect on pancreatic cancer xenograft mouse model in comparison to the intravenously injected free GEM and DDP combination. In addition, a strong synergistic therapeutic effect of the GEM-DDP/hydrogel system against pancreatic cancer has been found in vitro and in vivo compared to the single-drug loaded hydrogel composites. The obtained findings suggest this developed thermo-sensitive copolymer hydrogel system as a potential universal carrier for the localized targeted delivery of multi-drugs, for use in a variety of inoperable solid tumors.
Keywordslocalized drug delivery sustained release thermo-sensitive hydrogel combination therapy pancreatic cancer
Unable to display preview. Download preview PDF.
We gratefully acknowledge financial support from the National Natural Science Fund for Distinguished Young Scholars (No. 31525009), the National Natural Science Foundation of China (Nos. 31800797 and 31771096), the National Key Research and Development Program of China (No. 2017YFC1103502), the China Postdoctoral Science Foundation funded project (No. 2018M631094), the Postdoctoral Innovation Talents Support Program (No. BX20180207), and 1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University.
- Yang, C. B.; Chan, K. K.; Lin, W. J.; Soehartono, A. M.; Lin, G. M.; Toh, H.; Yoon, H. S.; Chen, C. K.; Yong, K. T. Biodegradable nanocarriers for small interfering ribonucleic acid (siRNA) co-delivery strategy increase the chemosensitivity of pancreatic cancer cells to gemcitabine. Nano Res. 2017, 10, 3049–3067.CrossRefGoogle Scholar
- Lee, H. S.; Park, S. W. Systemic chemotherapy in advanced pancreatic cancer. Gut Liver 2016, 10, 340–347.Google Scholar
- Bilalis, P.; Skoulas, D.; Karatzas, A.; Marakis, J.; Stamogiannos, A.; Tsimblouli, C.; Sereti, E.; Stratikos, E.; Dimas, K.; Vlassopoulos, D. et al. Self-healing pH-and enzyme stimuli-responsive hydrogels for targeted delivery of gemcitabine to treat pancreatic cancer. Biomacromolecules 2018, 19, 3840–3852.CrossRefGoogle Scholar
- Yang, W. J.; Zhou, P.; Liang, L. J.; Cao, Y. P.; Qiao, J. Q.; Li, X. H.; Teng, Z. G.; Wang, L. H. Nanogel-incorporated injectable hydrogel for synergistic therapy based on sequential local delivery of combretastatin-A4 phosphate (CA4P) and doxorubicin (DOX). ACS Appl. Mater. Interfaces 2018, 10, 18560–18573.CrossRefGoogle Scholar
- Mukherjee, S.; Hurt, C. N.; Bridgewater, J.; Falk, S.; Cummins, S.; Wasan, H.; Crosby, T.; Jephcott, C.; Roy, R.; Radhakrishna, G. et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial. Lancet Oncol. 2013, 14, 317–326.CrossRefGoogle Scholar
- Colucci, G.; Labianca, R.; Di Costanzo, F.; Gebbia, V.; Cartenì, G.; Massidda, B.; Dapretto, E.; Manzione, L.; Piazza, E.; Sannicolò, M. et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: The GIP-1 study. J. Clin. Oncol. 2010, 28, 1645–1651.CrossRefGoogle Scholar
- Wang, W. W.; Song, H. J.; Zhang, J.; Li, P.; Li, C.; Wang, C.; Kong, D. L.; Zhao, Q. An injectable, thermosensitive and multicompartment hydrogel for simultaneous encapsulation and independent release of a drug cocktail as an effective combination therapy platform. J. Control. Release 2015, 203, 57–66.CrossRefGoogle Scholar
- Besançon, O. G.; Tytgat, G. A. M.; Meinsma, R.; Leen, R.; Hoebink, J.; Kalayda, G. V.; Jaehde, U.; Caron, H. N.; van Kuilenburg, A. B. P. Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids. Cancer Lett. 2012, 319, 23–30.CrossRefGoogle Scholar
- Crul, M.; van Waardenburg, R. C. A. M.; Bocxe, S.; van Eijndhoven, M. A. J.; Pluim, D.; Beijnen, J. H.; Schellens, J. H. M. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem. Pharmacol. 2003, 65, 275–282.CrossRefGoogle Scholar